CL2011000922A1 - Composicion de vacuna que comprende un vector de expresion canarypox capaz de expresar en un equino proteinas virales del virus de la peste equina africana (ahsv) vp2 y vp5; y su uso para inducir una respuesta inmune protectora contra la peste equina africana en un animal equino. - Google Patents
Composicion de vacuna que comprende un vector de expresion canarypox capaz de expresar en un equino proteinas virales del virus de la peste equina africana (ahsv) vp2 y vp5; y su uso para inducir una respuesta inmune protectora contra la peste equina africana en un animal equino.Info
- Publication number
- CL2011000922A1 CL2011000922A1 CL2011000922A CL2011000922A CL2011000922A1 CL 2011000922 A1 CL2011000922 A1 CL 2011000922A1 CL 2011000922 A CL2011000922 A CL 2011000922A CL 2011000922 A CL2011000922 A CL 2011000922A CL 2011000922 A1 CL2011000922 A1 CL 2011000922A1
- Authority
- CL
- Chile
- Prior art keywords
- equine
- african horse
- horse sickness
- ahsv
- response against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12111—Orbivirus, e.g. bluetongue virus
- C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN DESCRIBE UNA COMPOSICIÓN DE VACUNA INMUNOGÉNICA CAPAZ DE PROVOCAR UNA<br /> RESPUESTA INMUNE PROTECTORA CONTRA LA PESTE EQUINA AFRICANA (AHSV) EN UN ANIMAL EQUINO, DONDE DICHA<br /> CORNPOSÍCÍÓ-I COMPRENDE: A) UN VECTOR DE CANARYPOX QUE COMPRENDE UNA MOLÉCULA DE ÁCIDO NUCLEÍCO QUE<br /> COMPRENDE DOS SECUENCIAS DE POLINUCLEÓTIDOS, DONDE DICHA MOLÉCULA DE ÁCIDO NUCLEÍCO CODIFICA Y ES CAPAZ<br /> DE EXPRESA. IN VIVO EN EL EQUINO, LOS POLIPÉPTIDOS VP2 Y VPS DEL VIRUS DE LA PESTE EQUINA AFRICANA; Y B) UN<br /> VEHÍCULO, DILUYENTE O EXCIPIENTE VETERINARIAMENTE ACEPTABLE. ADICIONALMENTE, DESCRIBE EL USO DE DICHA<br /> COMPOSICIÓN DE VACUNA INMUNOGÉNICA PARA LA PREPARACIÓN DE UN MEDICAMENTO ÚTIL PARA PROVOCAR UNA<br /> RESPUESTA INMUNE PROTECTORA CONTRA LA PESTE EQUINA AFRICANA EN UN ANIMAL EQUINO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10807508P | 2008-10-24 | 2008-10-24 | |
US16351709P | 2009-03-26 | 2009-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000922A1 true CL2011000922A1 (es) | 2011-09-16 |
Family
ID=41818403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000922A CL2011000922A1 (es) | 2008-10-24 | 2011-04-21 | Composicion de vacuna que comprende un vector de expresion canarypox capaz de expresar en un equino proteinas virales del virus de la peste equina africana (ahsv) vp2 y vp5; y su uso para inducir una respuesta inmune protectora contra la peste equina africana en un animal equino. |
Country Status (19)
Country | Link |
---|---|
US (3) | US8168200B2 (es) |
EP (1) | EP2358742B1 (es) |
JP (1) | JP2012506699A (es) |
KR (1) | KR101719005B1 (es) |
CN (1) | CN102245627A (es) |
AP (1) | AP3334A (es) |
AR (1) | AR074055A1 (es) |
AU (1) | AU2009308331C1 (es) |
BR (2) | BRPI0920622B1 (es) |
CA (1) | CA2741333C (es) |
CL (1) | CL2011000922A1 (es) |
EA (1) | EA024111B1 (es) |
ES (1) | ES2681693T3 (es) |
MX (1) | MX2011004219A (es) |
NZ (2) | NZ598605A (es) |
PL (1) | PL2358742T3 (es) |
PT (1) | PT2358742T (es) |
WO (1) | WO2010048394A2 (es) |
ZA (1) | ZA201103031B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0920622B1 (pt) * | 2008-10-24 | 2019-11-12 | Merial, Inc. | vacina contra o vírus da doença equina africana |
CN104203271B (zh) | 2012-02-14 | 2017-08-25 | 梅里亚股份有限公司 | 表达狂犬病病毒和ox40蛋白的重组痘病毒载体及从其制造的疫苗 |
WO2016071850A1 (en) * | 2014-11-04 | 2016-05-12 | Deltamune (Pty) Limited | Live attenuated african horsesickness virus |
US10574993B2 (en) | 2015-05-29 | 2020-02-25 | Qualcomm Incorporated | Coding data using an enhanced context-adaptive binary arithmetic coding (CABAC) design |
EA202092165A1 (ru) * | 2018-03-19 | 2021-02-25 | Бёрингер Ингельхайм Ветмедика Гмбх | Новый ehv сайт инсерции ul43 |
CN116041447A (zh) * | 2022-12-29 | 2023-05-02 | 北京亿森宝生物科技有限公司 | 一种检测非洲马瘟病毒的试剂盒及其应用 |
CN116656731B (zh) * | 2023-05-25 | 2024-04-12 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
JP3602530B2 (ja) * | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
ZA976424B (en) * | 1996-07-05 | 1999-01-22 | Agricultural Research Council | Nucleic acid sequences coding for african horsesickness virus outer capsid components |
FR2775601B1 (fr) * | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
FR2776928B1 (fr) * | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
US7740863B2 (en) * | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
US7862821B2 (en) * | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
BRPI0920622B1 (pt) * | 2008-10-24 | 2019-11-12 | Merial, Inc. | vacina contra o vírus da doença equina africana |
-
2009
- 2009-10-22 BR BRPI0920622-1A patent/BRPI0920622B1/pt active IP Right Grant
- 2009-10-22 KR KR1020117011832A patent/KR101719005B1/ko active IP Right Grant
- 2009-10-22 PL PL09760655T patent/PL2358742T3/pl unknown
- 2009-10-22 WO PCT/US2009/061669 patent/WO2010048394A2/en active Application Filing
- 2009-10-22 PT PT97606552T patent/PT2358742T/pt unknown
- 2009-10-22 AP AP2011005954A patent/AP3334A/xx active
- 2009-10-22 MX MX2011004219A patent/MX2011004219A/es active IP Right Grant
- 2009-10-22 CA CA2741333A patent/CA2741333C/en active Active
- 2009-10-22 EA EA201100674A patent/EA024111B1/ru unknown
- 2009-10-22 EP EP09760655.2A patent/EP2358742B1/en active Active
- 2009-10-22 JP JP2011533331A patent/JP2012506699A/ja active Pending
- 2009-10-22 CN CN2009801492091A patent/CN102245627A/zh active Pending
- 2009-10-22 NZ NZ598605A patent/NZ598605A/en unknown
- 2009-10-22 AU AU2009308331A patent/AU2009308331C1/en active Active
- 2009-10-22 NZ NZ592388A patent/NZ592388A/en unknown
- 2009-10-22 ES ES09760655.2T patent/ES2681693T3/es active Active
- 2009-10-22 US US12/604,048 patent/US8168200B2/en active Active
- 2009-10-22 BR BR122019001455-8A patent/BR122019001455B1/pt active IP Right Grant
- 2009-10-23 AR ARP090104083A patent/AR074055A1/es active IP Right Grant
-
2011
- 2011-04-21 CL CL2011000922A patent/CL2011000922A1/es unknown
- 2011-04-21 ZA ZA2011/03031A patent/ZA201103031B/en unknown
-
2012
- 2012-01-25 US US13/357,755 patent/US20120114691A1/en not_active Abandoned
-
2013
- 2013-10-22 US US14/060,023 patent/US20140120133A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000922A1 (es) | Composicion de vacuna que comprende un vector de expresion canarypox capaz de expresar en un equino proteinas virales del virus de la peste equina africana (ahsv) vp2 y vp5; y su uso para inducir una respuesta inmune protectora contra la peste equina africana en un animal equino. | |
Jung et al. | Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus | |
AR125268A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
ES2662801T3 (es) | Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas | |
EP3156070A3 (en) | Newcastle disease virus vectored herpesvirus vaccines | |
Zhang et al. | Enhanced protective immunity against spring viremia of carp virus infection can be induced by recombinant subunit vaccine conjugated to single-walled carbon nanotubes | |
EP2998315A3 (en) | Newcastle disease virus vectored avian vaccines | |
EA201990718A1 (ru) | Векторы аденовируса собачьих | |
EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
EA201400912A1 (ru) | Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе | |
BR112013030150A2 (pt) | proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma | |
MX2011007692A (es) | Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion. | |
PH12013501116A1 (en) | Raccoon poxvirus expressing rabies glycoproteins | |
CL2013001877A1 (es) | Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus. | |
EA201491513A1 (ru) | Рекомбинантные штаммы escherichia coli | |
AR105482A1 (es) | Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso | |
CO6541529A2 (es) | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos | |
AR081409A1 (es) | PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV) | |
AR076437A1 (es) | Composicion inmunologica, equipo para provocar una respuesta inmune y metodo para provocar una respuesta inmune contra befv en un animal | |
WO2018102774A3 (en) | Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a | |
Palacios et al. | Evaluation of the immune response to Anaplasma marginale MSP5 protein using a HSV-1 amplicon vector system or recombinant protein | |
Zeng et al. | Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice | |
AR084095A1 (es) | Peptidos tomm34 y vacunas que los incluyen | |
BR112014001287A2 (pt) | vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina |